Sage Therapeutics, Inc. (SAGE) News
Filter SAGE News Items
SAGE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SAGE News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SAGE News From Around the Web
Below are the latest news stories about SAGE THERAPEUTICS INC that investors may wish to consider to help them evaluate SAGE as an investment opportunity.
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., January 12, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. |
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from BiogenCAMBRIDGE, Mass., January 10, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("The Company"), today confirmed that Biogen Inc. (Nasdaq: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. |
Biogen proposes to buy remaining stake in Sage in $442 million dealAs per the filing, Biogen has a 10.2% stake in Sage Therapeutics. Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States after concerns over cost, efficacy and side effects. Sage, whose shares fell 74.9% last year, abandoned the development of its drug dalzanemdor after multiple trial failures. |
Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025CAMBRIDGE, Mass., January 08, 2025--Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. |
Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 42% in Sage Therapeutics (SAGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Sage Therapeutics price target lowered to $6 from $10 at StifelStifel lowered the firm’s price target on Sage Therapeutics (SAGE) to $6 from $10 and keeps a Hold rating on the shares. 2024 was “a challenging year,” with shares down about 75% following the failure/discontinuation of SAGE-718, Stifel notes. Sage has “an arguably overqualified CEO” in Barry Greene who the firm thinks is committed to Sage and helping the company re-build itself, the analyst stated. It “seems plausible” that the next leg of investment could be via a combination of advancing inte |
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceCAMBRIDGE, Mass., November 26, 2024--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. |
Sage Therapeutics price target lowered to $4 from $7 at BofABofA lowered the firm’s price target on Sage Therapeutics (SAGE) to $4 from $7 and keeps an Underperform rating on the shares after the company reported that the phase 2 DIMENSION trial evaluating dalzanemdor in cognitive impairment associated with Huntington’s disease did not meet the primary endpoint. The firm, which is removing $75M in pipeline value from its model based on the update, notes the company had highlighted other assets in the early-stage pipeline and says it thinks “significant c |
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC SaysSage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says |